About Soleno Therapeutics, Inc. - Common Stock (SLNO)
Soleno Therapeutics Inc is a biopharmaceutical company focused on developing innovative therapies for rare diseases, particularly those associated with genetic and metabolic disorders. The company is committed to addressing significant unmet medical needs by advancing its proprietary treatment candidates through clinical trials. With an emphasis on leveraging cutting-edge science and research, Soleno aims to bring novel solutions to patients suffering from conditions like Prader-Willi syndrome, thereby enhancing their quality of life and overall health outcomes. Read More
The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Soleno Therapeutics, Inc. (NASDAQ: SLNO) focused on whether Soleno and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors.
NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Agilon Health, Inc. (NYSE:AGL), Soleno Therapeutics, Inc. (NASDAQ:SLNO), AVITA Medical, Inc. (NASDAQ:RCEL), and Coty, Inc. (NYSE:COTY). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Soleno Therapeutics, Inc. (NASDAQ: SLNO) resulting from allegations that Soleno Therapeutics may have issued materially misleading business information to the investing public.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Soleno (SLNO) To Contact Him Directly To Discuss Their Options
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Soleno (SLNO) To Contact Him Directly To Discuss Their Options
NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ: SLNO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Acadia's Phase 3 Compass Prader-Willi syndrome trial failed to meet endpoints, but the company projects $1 billion in sales in 2025 and highlights a strong pipeline outlook.
